CVE:BCT BriaCell Therapeutics (BCT) Stock Price, News & Analysis C$10.60 -0.42 (-3.81%) (As of 12/30/2021) Add Compare Share Share Stock Analysis Stock Analysis About BriaCell Therapeutics Stock (CVE:BCT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BriaCell Therapeutics alerts:Sign Up Key Stats Today's RangeC$10.60▼C$11.0750-Day RangeC$10.60▼C$10.6052-Week RangeC$3.50▼C$15.75Volume3,402 shsAverage Volume12,671 shsMarket CapitalizationC$168.68 millionP/E RatioN/ADividend YieldN/APrice TargetC$15.00Consensus RatingN/A Company OverviewBriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.Read More… War on Elon Escalates… (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. Receive BCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BriaCell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCT Stock News HeadlinesBriaCell Therapeutics Confronts Financial Challenges Amid Volatile Markets and Potential Shareholder DilutionOctober 31, 2024 | markets.businessinsider.comBriaCell’s Promising Breast Cancer Study ResultsOctober 22, 2024 | markets.businessinsider.comI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. November 5, 2024 | Porter & Company (Ad)BriaCell Therapeutics Corp.: BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival DataOctober 22, 2024 | finanznachrichten.deBriaCell Therapeutics advances Phase 3 MBC clinical studyOctober 16, 2024 | msn.comBCT:CA BriaCell Therapeutics Corp.September 21, 2024 | seekingalpha.comBriaCell Therapeutics Corp. (BCTXW)September 18, 2024 | ca.finance.yahoo.comBriaCell Says FDA Authorizes Expanded Access Policy For Patients With Metastatic Breast CancerSeptember 18, 2024 | markets.businessinsider.comSee More Headlines BCT Stock Analysis - Frequently Asked Questions How have BCT shares performed this year? BriaCell Therapeutics' stock was trading at C$10.60 at the beginning of the year. Since then, BCT stock has increased by 0.0% and is now trading at C$10.60. View the best growth stocks for 2024 here. How do I buy shares of BriaCell Therapeutics? Shares of BCT stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of BriaCell Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that BriaCell Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), BMO MSCI India ESG Leaders Index ETF (ZID), Athersys (ATHX), Anavex Life Sciences (AVXL), Gene Biotherapeutics (CRXM) and Inovio Pharmaceuticals (INO). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:BCT CUSIPN/A CIKN/A Webwww.briacell.com Phone+1-604-9211810FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$15.00 High Stock Price TargetC$15.00 Low Stock Price TargetC$15.00 Potential Upside/Downside+41.5%Consensus Rating Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.05 Current Ratio129.63 Quick Ratio128.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$3.34 per share Price / Cash Flow3.17 Book ValueC$3.60 per share Price / Book2.94Miscellaneous Outstanding Shares15,913,000Free FloatN/AMarket CapC$168.68 million OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (CVE:BCT) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.